Chronic myeloid leukemia (CML) is one of the most common leukemias occurring in the
adult population. The course of CML is divided into three phases: the chronic phase, the …

The incidence of chronic myeloid leukemia (CML) ranges between 10 and 15
cases/106/year (age adjusted) without any major geographic or ethnic differences [1]. The …

New insights have emerged from maturing long-term academic and commercial clinical
trials regarding optimum management of chronic myeloid leukemia (CML). Velocity of …

Current treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKI) is
effective in many patients, but is not curative and frequently limited by intolerance or …

Imatinib mesylate was the first tyrosine kinase inhibitor (TKI) approved for the management
of chronic myeloid leukemia. Imatinib produces acceptable responses in approximately 60 …

Chronic myelogenous leukemia represents 7–20% of all leukemia cases, with a worldwide
incidence projected at less than one to two per 100,000 people. Approximately 85% of …

Chronic myelogenous leukemia (CML) is an indolent malignant hematological disease that
accounts for about 15% of all cases of leukemia. This disorder results from the formation of …

Deregulated activity of BCR-ABL1, a nonreceptor tyrosine kinase encoded by the fusion
gene resulting from the t (9; 22)(q34; q11) chromosomal translocation, is thought to be the …

The 2014 NCCN Clinical Practice Guidelines in Oncology for Chronic Myelogenous
Leukemia recommend quantitative reverse-transcription polymerase chain reaction (QPCR) …

Chronic myeloid leukemia (CML) is a myeloproliferative disorder that affects 5000 new
patients per year in the United States. Prior to 10years ago, durable remission was rare and …